Active	Status	Sponsor type	Region	Phase	Filter
9 Active 2 Inactive 11 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

9 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Williams, Patrick
SIGLEC, NCT05839041: A Multiple Dose Study of AVD-104 for Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)	Recruiting	2	300	US	AVD-104, Avacincaptad	Aviceda Therapeutics, Inc.	Geographic Atrophy of the Macula, Macular Degeneration	06/25	06/26
NCT06116916: Study to Assess the Efficacy & Safety of KHK4951 in Patients With Diabetic Macular Edema	Recruiting	2	150	Japan, US, RoW	KHK4951, Aflibercept Injection	Kyowa Kirin, Inc.	Diabetic Macular Edema (DME)	11/25	12/25
NCT06116890: Study to Assess the Efficacy & Safety of KHK4951 in Patients With Neovascular Age-Related Macular Degeneration	Recruiting	2	180	Japan, US, RoW	KHK4951, Aflibercept Injection	Kyowa Kirin, Inc.	Neovascular Age-Related Macular Degeneration (nAMD)	11/25	12/25
NCT05230537: A Masked, Placebo-controlled Study to Assess Iptacopan in Age-related Macular Degeneration	Recruiting	2	146	Europe, US, RoW	Iptacopan (LNP023), Placebo	Novartis Pharmaceuticals	Age-Related Macular Degeneration	10/26	10/26
NCT05893537: Study to Evaluate the Efficacy and Safety of Oral CT1812 in Participants With Geographic Atrophy (GA) Secondary to Dry Age-Related Macular Degeneration (AMD).	Recruiting	2	246	US	Active Comparator CT1812, Placebo Comparator	Cognition Therapeutics	Age-Related Macular Degeneration	07/27	08/27
PREDICT, NCT03448926: The Registry for DCIS Patients With DCISionRT Testing	Suspended	N/A	2500	US, RoW	Treatment Recommendation Surveys	PreludeDx, University of South Florida	DCIS	11/25	11/35
Gerstenblith, Adam T
NCT06116916: Study to Assess the Efficacy & Safety of KHK4951 in Patients With Diabetic Macular Edema	Recruiting	2	150	Japan, US, RoW	KHK4951, Aflibercept Injection	Kyowa Kirin, Inc.	Diabetic Macular Edema (DME)	11/25	12/25
Kerrison, John
NCT04740671 / 2020-005364-57: A Phase 3 Study to Compare the Efficacy and Safety of HLX04-O With Ranibizumab in Subjects With wAMD	Active, not recruiting	3	388	Europe, US, RoW	HLX04-O, ranibizumab	Shanghai Henlius Biotech	Age Related Macular Degeneration	12/24	03/25
NCT06116916: Study to Assess the Efficacy & Safety of KHK4951 in Patients With Diabetic Macular Edema	Recruiting	2	150	Japan, US, RoW	KHK4951, Aflibercept Injection	Kyowa Kirin, Inc.	Diabetic Macular Edema (DME)	11/25	12/25